Orthocell Limited (ASX:OCC)


right-arrow Created with Sketch. 0 (0%)
MCAP $100.0M
Last trade 16.16pm 07/12/2021 20mins delayed

Latest Announcements

07/12/2021 Price SensitivePSOCCOrthocell Limited
18/11/2021OCCOrthocell Limited
18/11/2021OCCOrthocell Limited
15/11/2021 Price SensitivePSOCCOrthocell Limited
09/11/2021OCCOrthocell Limited
09/11/2021OCCOrthocell Limited
29/10/2021 Price SensitivePSOCCOrthocell Limited
28/10/2021OCCOrthocell Limited

Company Overview

Orthocell Limited is an Australia-based regenerative medicine company. The Company is engaged in the development and commercialization of cell therapies and biological medical devices. The Company offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. It represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The Company has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC in the news

Orthocell’s (OCC) shoulder tendon study database has been locked, with the study…
Orthocell (OCC) announces positive data from pre-clinical study for anterior cruciate ligament…
Regenerative medicine company Orthocell (OCC) secures patents in Canada and Hong Kong…
Orthocell (OCC) sees its final patient complete their 12-month follow-up visit as…

Search Previous Announcements